Search for drugs:
Typing the drug name to query
GEMTUZUMAB OZOGAMICIN
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- WARNINGS AND PRECAUTIONS
- QT Interval Prolongation
- QT interval prolongation has been observed in patients treated with other drugs containing calicheamicin. When administering MYLOTARG to patients who have a history of or predisposition for QTc prolongation, who are taking medicinal products that are known to prolong QT interval, and in patients with electrolyte disturbances, obtain electrocardiograms (ECGs) and electrolytes prior to the start of treatment and as needed during administration.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
7
24085
Other ADRs
8406
38373181
Odds Ratio = 1.327
Drug Property Information
ATC Code(s):
- L01XC05 - gemtuzumab ozogamicin
- L01XC - Monoclonal antibodies
- L01X - OTHER ANTINEOPLASTIC AGENTS
- L01 - ANTINEOPLASTIC AGENTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Active Ingredient:GEMTUZUMAB OZOGAMICIN
Active Ingredient UNII:8GZG754X6M
Drugbank ID:DB00056
PubChem Compound:N/ADIR Classification
CAS Number:
Dosage Form(s):injection, powder, lyophilized, for solution
Route(s) Of Administrator:intravenous
Daily Dose:
Chemical Structure: 
SMILE Code:
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.